Depression—An Emerging Indication for Botulinum Toxin Treatment
This 2015 literature review by Kruger and Wollmer explores the potential of botulinum toxin type A (BoNT-A) as a treatment for major depressive disorder (MDD). The authors discuss the facial feedback hypothesis, which suggests that facial expressions can influence emotional experiences. By injecting BoNT-A into the glabellar region (frown lines),
June 26, 2025
No Comments